Exact Sciences Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXAS research report →
Companywww.exactsciences.com
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.
- CEO
- Kevin T. Conroy
- IPO
- 2001
- Employees
- 6,900
- HQ
- Madison, WI, US
Price Chart
Valuation
- Market Cap
- $20.03B
- P/E
- -95.72
- P/S
- 6.17
- P/B
- 8.29
- EV/EBITDA
- 506.73
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 69.69%
- Op Margin
- -6.17%
- Net Margin
- -6.40%
- ROE
- -8.51%
- ROIC
- -4.05%
Growth & Income
- Revenue
- $3.25B · 17.69%
- Net Income
- $-207,949,000 · 79.79%
- EPS
- $-1.10 · 80.32%
- Op Income
- $-99,079,000
- FCF YoY
- 378.60%
Performance & Tape
- 52W High
- $104.98
- 52W Low
- $38.81
- 50D MA
- $103.02
- 200D MA
- $74.29
- Beta
- 1.44
- Avg Volume
- 2.53M
Get TickerSpark's AI analysis on EXAS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 23, 26 | Baranick Brian | other | 33,321 |
| Mar 23, 26 | Baranick Brian | sell | 795 |
| Mar 23, 26 | Baranick Brian | sell | 28,063 |
| Mar 23, 26 | Herriott James | sell | 1,762 |
| Mar 23, 26 | Herriott James | sell | 793 |
| Mar 23, 26 | Herriott James | sell | 2,861 |
| Mar 23, 26 | Herriott James | sell | 20,321 |
| Mar 23, 26 | Bloomer Aaron | other | 89,911 |
| Mar 23, 26 | Bloomer Aaron | sell | 417 |
| Mar 23, 26 | Bloomer Aaron | sell | 28,063 |
Our EXAS Coverage
We haven't published any research on EXAS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EXAS Report →